Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017630 | 0.81 | TP53 (0.31) | — | |
| SCHEMBL6573446 | 0.81 | FAAH (0.34) | ALDH1A1 | |
| SCHEMBL9811868 | 0.79 | HSD17B10 (0.32) | NR1H2ALDH1A1 | |
| SCHEMBL4714174 | 0.78 | NR1H2 (0.34) | NR1H2 | |
| SCHEMBL4711556 | 0.77 | ALDH1A1 (0.31) | ALDH1A1GLA | |
| SCHEMBL7275965 | 0.77 | NR1H2 (0.35) | NR1H2ALDH1A1GLA | |
| SCHEMBL5691656 | 0.75 | NPSR1 (0.45) | ALDH1A1 | |
| SCHEMBL5172213 | 0.73 | ABCG2 (0.35) | ALDH1A1 | |
| SCHEMBL163219 | 0.73 | ABCG2 (0.32) | ALDH1A1 | |
| SCHEMBL7456710 | 0.72 | CA12 (0.33) | ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276724-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20010051642-A1 | Method for treating Alzheimer's disease | AHN KYUNGHYE (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001079179-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051642-A1 | Method for treating Alzheimer's disease | BACE1, BACE2, PSEN1 | NR1H2 14/4885CTSS 1198/4885CTSK 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.